Agile Therapeutics (AGRX) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price targets for Agile Therapeutics' shares. Their AGRX share price forecasts range from $5.00 to $12.00. On average, they expect the company's share price to reach $8.50 in the next year. This suggests a possible upside of 356.0% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.

Agile Therapeutics' stock was trading at $0.2270 at the beginning of the year. Since then, AGRX stock has increased by 721.1% and is now trading at $1.8639.
View the best growth stocks for 2023 here.

Agile Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 10,700 shares, a decline of 48.3% from the August 15th total of 20,700 shares. Based on an average daily volume of 119,400 shares, the short-interest ratio is presently 0.1 days. Currently, 0.6% of the shares of the stock are sold short.
View Agile Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AGRX earnings forecast.

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings data on Wednesday, August, 9th. The specialty pharmaceutical company reported ($3.10) EPS for the quarter, beating analysts' consensus estimates of ($3.48) by $0.38. The specialty pharmaceutical company earned $5.50 million during the quarter, compared to analyst estimates of $4.68 million. Agile Therapeutics had a negative net margin of 201.02% and a negative trailing twelve-month return on equity of 2,658.43%.

Agile Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Agile Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $21.66 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Agile Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (1.10%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends.

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGRX stock can currently be purchased for approximately $1.86.

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.60 million and generates $10.88 million in revenue each year. The specialty pharmaceutical company earns $-25,410,000.00 in net income (profit) each year or ($39.56) on an earnings per share basis.

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.